1609 CXCR1/2 inhibition ameliorates clinical lesions in experimental mucous membrane pemphigoid

Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease that most frequently affects the oral cavity and conjunctivae. Additional skin lesions may appear in about a quarter of patients. The current therapeutic armamentarium mainly based on long-term immunosuppression, which associated with high number adverse events not effective. Here, we investigated effects topical conjunctival administration selective CXCR1/2 inhibitor (DF2156A) MMP mouse model. was induced C57BL6/J mice by repetitive injections anti-murine laminin α3 IgG. Mice were treated eyedrops twice daily for 12 28 days. At both timepoints, DF2156A compared vehicle control group, reduced split formation 50%, as determined H&E staining biopsies. In addition, day 28, decreased inflammatory infiltrate observed upon treatment. Our data indicate pharmacological inhibition represents promising treatment MMP. particular, application appeared novel avenue patients ocular involvement.